This study focuses on women with advanced forms of ovarian cancer, peritoneal cancer, and fallopian tube cancer that have become resistant to platinum-based treatments. The research examines a new medication called TORL-1-23, which is a specialized antibody drug that targets a specific protein called CLDN6 found in these cancers. The purpose is to evaluate how well TORL-1-23 works and how safe it is when used alone in treating these types of cancer.
The treatment involves receiving TORL-1-23 through an intravenous infusion (given directly into a vein). During the study, participants may also receive pegfilgrastim, a supportive medication that helps the body produce white blood cells after treatment. The study treatment may continue for up to 24 months, depending on how well participants respond to the therapy.
The study medication TORL-1-23 is designed to specifically target cancer cells that have the CLDN6 protein on their surface. It works by delivering a cancer-fighting substance directly to these cells while aiming to minimize effects on healthy cells. This targeted approach represents a new way of treating these types of cancer that no longer respond to standard platinum-based treatments.
Austria 
Belgium 
Czechia 
France 
Germany 
Ireland 
Italy 
Spain 
